As per MRFR analysis, the US Metagenomic Sequencing Market Size was estimated at 139.2 (USD Million) in 2023. The US Metagenomic Sequencing Market Industry is expected to grow from 163.2(USD Million) in 2024 to 905 (USD Million) by 2035. The US Metagenomic Sequencing Market CAGR (growth rate) is expected to be around 16.85% during the forecast period (2025 - 2035).
The US Metagenomic Sequencing Market is experiencing several important trends driven by advancements in technology and the increasing demand for precision medicine. One key market driver is the rising prevalence of infectious diseases, coupled with the need for rapid and accurate diagnostic tools. This has led to greater investment in research and development, as well as collaborations between public health authorities and private companies.
Additionally, the growing emphasis on microbiome research is creating opportunities for applications in various fields, including pharmaceuticals, agriculture, and environmental monitoring. Recent trends reflect an increasing adoption of metagenomic sequencing in clinical settings, particularly for identifying pathogens in complex samples where traditional culture methods may fail.
The US government has been actively supporting initiatives to enhance bioinformatics infrastructure which is crucial for analyzing vast amounts of sequencing data. Furthermore, the integration of artificial intelligence and machine learning in data analysis is streamlining research processes and enhancing the precision of results.
Opportunities within the US market include expanding applications of metagenomic sequencing beyond clinical diagnostics to include personalized medicine and the development of novel therapeutics targeting the microbiome. The rising awareness and adoption of personalized healthcare approaches among the US population can propel further growth in this domain.
Regulatory support from institutions like the FDA is also enabling the approval of innovative metagenomic technologies at a faster pace. Overall, the dynamic intersection of technology, healthcare needs, and regulatory frameworks is shaping a vibrant landscape for the US Metagenomic Sequencing Market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Metagenomic Sequencing Market Industry is experiencing an increasing demand for personalized medicine, driven by the rising awareness of genomics and its applications in treatment customization. According to a report by the National Institutes of Health (NIH), personalized medicine is projected to significantly enhance patient outcomes.
As of 2022, the National Cancer Institute reported that roughly 1.9 million new cancer cases were diagnosed in the US, emphasizing the need for targeted therapies that can be determined through advanced sequencing technologies. This reflects a broader trend toward precision health strategies, which could lead to a rise in the adoption of metagenomic sequencing capabilities to tailor treatments.
Research and Development investment from top biopharmaceutical companies, such as Amgen and Gilead Sciences, is also contributing to this growth, pushing the boundaries of how cancer and other diseases can be treated.
The US Metagenomic Sequencing Market Industry is benefiting from heightened Research and Development activities in biotechnology and pharmaceuticals. The US government has invested heavily in genomics research, with the Department of Health and Human Services announcing funding of over USD 1 billion for such initiatives in 2023.
This inflow of funding is expected to accelerate innovation and application of metagenomic sequencing technologies. Moreover, organizations like the Broad Institute and Stanford University are conducting extensive R&D in metagenomics, which not only enhances scientific knowledge but also drives available commercial applications, thereby facilitating market growth within the US.
There is an increasing awareness of the importance of infectious disease diagnostics in the US, significantly impacting the US Metagenomic Sequencing Market Industry. The Centers for Disease Control and Prevention (CDC) reported that infectious diseases account for approximately 3 million hospitalizations annually in the US.
With the growing threat of emerging infectious diseases, the demand for rapid and accurate diagnostic methods utilizing metagenomic sequencing is expected to rise. This is further underscored by the impact of the Covid-19 pandemic, which has spotlighted the importance of dynamic and rapid pathogen detection capabilities in public health strategies, driving investments from organizations like Illumina and Thermo Fisher Scientific into innovative sequencing solutions.
The US Metagenomic Sequencing Market is witnessing significant evolution within its Product and Service segment, which encompasses essential components such as Reagents and Consumables, Instruments, and Services. Reagents and Consumables remain critical to the market, as they provide the necessary materials for sample processing and analysis.
The importance of high-quality reagents is underscored by their direct impact on the accuracy and reliability of sequencing results, making them a crucial aspect of successful metagenomic studies. Instruments play a pivotal role in advancing the capabilities of metagenomic sequencing, as innovative technologies facilitate higher throughput and improved data generation efficiency.
As the need for comprehensive genomic data continues to rise in research and clinical applications, cutting-edge instrumentation is poised to dominate the market landscape, driving further advancements in metagenomics. Services within this segment are also gaining traction, providing essential support such as data analysis, bioinformatics, and project consultation, which assist researchers and institutions in navigating the complexities of metagenomic data interpretation.
The demand for specialized services highlights the growing reliance on expert knowledge in the field, as well as the increasing importance of collaboration between service providers and researchers. Collectively, these components of the Product and Service segment not only address current market needs but also contribute to the ongoing expansion and growth within the US Metagenomic Sequencing Market, reinforcing the sector’s potential in diverse applications ranging from environmental studies to human health investigations.
As the landscape changes, the continuous improvement in technologies and offerings will pave the way for enhanced research capabilities and new opportunities, further solidifying the significance of these elements in the overall market dynamics. Through such advancements, this segment plays an integral role in shaping the future of genomic research and personalized medicine in the United States.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The US Metagenomic Sequencing Market, particularly in the Technology segment, plays a crucial role in advancing our understanding of microbial diversity and functionality. Techniques such as Shotgun Metagenomic Sequencing allow for comprehensive analyses of complex microbial communities, making it essential for environmental monitoring and clinical diagnostics.
Meanwhile, 16s rRNA Sequencing stands out for its precision in identifying and classifying bacteria, serving as a foundational method in both research and clinical settings. Moreover, Whole Genome Sequencing and De Novo Assembly are pivotal in unraveling the genomes of various organisms, leading to significant discoveries in genomics and microbiomics.
The Metatranscriptomic approach further enhances this by providing insights into gene expression within microbial communities, which has implications for health and disease management. With these technologies, the US Metagenomic Sequencing Market is positioned to enrich our understanding of microbial ecosystems, contributing significantly to fields such as healthcare, agriculture, and environmental science.
Overall, these techniques drive innovation while offering vast opportunities for research, product development, and applications across numerous industries.
The competitive landscape of the US Metagenomic Sequencing Market is characterized by rapid advancements in technology and a growing emphasis on personalized medicine. As researchers and clinicians increasingly recognize the importance of understanding complex microbial communities, metagenomic sequencing has emerged as a powerful tool for elucidating the functionalities and interactions of diverse organisms.
This burgeoning market is marked by the presence of several key players focused on innovation, scalability, and integration of cutting-edge sequencing technologies. Given the diverse applications of metagenomic sequencing in areas like environmental monitoring, agriculture, and clinical diagnostics, companies are vying for a significant share of the market by developing novel platforms and establishing strategic partnerships.
These dynamics contribute to a competitive environment where research and development play a critical role in staying ahead of the curve and meeting the evolving demands of the healthcare landscape. Illumina stands out prominently in the US Metagenomic Sequencing Market, leveraging its robust technology and innovative solutions to bolster its market presence.
This company has established itself as a leading force in the field of sequencing by providing high-throughput, scalable, and cost-effective solutions that cater to a wide array of applications in metagenomics. Illumina's strengths lie in its extensive portfolio of sequencers and comprehensive analysis software, which are critical for researchers aiming to generate high-quality data from complex biological samples.
Additionally, the company has invested significantly in advancing its technology, focusing on enhancing accuracy and throughput while reducing costs, which positions it well against emerging competitors. Illumina's strategic partnerships and collaborations with academic institutions and research organizations also strengthen its influence within the market, reinforcing its reputation as a pioneer in metagenomic sequencing.
BioRad Laboratories also plays a vital role in the US Metagenomic Sequencing Market, offering a diverse range of products and services that complement metagenomic research. The company's portfolio includes advanced reagents, instruments, and software solutions tailored to the needs of researchers engaged in microbial genomics and microbiome studies.
BioRad's strengths lie in its commitment to delivering high-quality products that facilitate accurate and efficient data generation. The company's established market presence is bolstered by its strong relationships with academic and commercial research institutions, enabling collaborative ventures that enhance product development and innovation.
Furthermore, BioRad's strategic mergers and acquisitions have expanded its capabilities within the life sciences sector, allowing it to integrate complementary technologies and broaden its portfolio. This strategic approach not only strengthens BioRad's position in the metagenomic sequencing market but also affirms its commitment to advancing scientific research and discovery in the US.
The US Metagenomic Sequencing Market has recently seen significant developments with companies like Illumina and Thermo Fisher Scientific advancing their product offerings aimed at enhancing genomic research, particularly in areas like environmental and clinical microbiology. In September 2023, Illumina announced the launch of its latest sequencing platform designed to streamline workflows, which has garnered attention in the research community.
Growth in market valuation for companies involved in metagenomic sequencing, including BioRad Laboratories and Agilent Technologies, reflects a rising demand for innovative diagnostic tools amid increasing emphasis on personalized medicine. Additionally, in August 2023, F. Hoffmann-La Roche expanded its genomic capabilities through the acquisition of a key technology firm, further consolidating its position in the market.
Current affairs also highlight collaborations among companies such as Oxford Nanopore Technologies and Genomatix to enhance data analysis techniques in metagenomic studies. Over the past few years, investments in research by Merck KGaA and Qiagen have driven advancements in metagenomic technologies, with the US government advocating for increased funding for genomic research initiatives.
This momentum indicates a future ripe with potential for advancements in metagenomic sequencing in the US market.
| Report Attribute/Metric Source: | Details |
| MARKET SIZE 2018 | 139.2(USD Million) |
| MARKET SIZE 2024 | 163.2(USD Million) |
| MARKET SIZE 2035 | 905.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 16.85% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| MARKET FORECAST PERIOD | 2025 - 2035 |
| HISTORICAL DATA | 2019 - 2024 |
| MARKET FORECAST UNITS | USD Million |
| KEY COMPANIES PROFILED | Illumina, BioRad Laboratories, Element Biosciences, F. HoffmannLa Roche, PerkinElmer, Thermo Fisher Scientific, Agilent Technologies, Genomatix, PacBio, Roche, Array BioPharma, BGI Genomics, Merck KGaA, Qiagen, Oxford Nanopore Technologies |
| SEGMENTS COVERED | Product & Service, Technology |
| KEY MARKET OPPORTUNITIES | Rising demand for personalized medicine, Advancements in sequencing technologies, Increasing prevalence of infectious diseases, Expanding applications in agriculture, Growth in research funding and investments |
| KEY MARKET DYNAMICS | Rapid technological advancements, Increasing demand for personalized medicine, Growing research funding, Rising prevalence of infectious diseases, Expanding applications in environmental monitoring |
| COUNTRIES COVERED | US |
Frequently Asked Questions (FAQ) :
The US Metagenomic Sequencing Market is expected to be valued at 163.2 million USD in 2024.
By 2035, the market is anticipated to reach a value of 905.0 million USD.
The market is projected to grow at a CAGR of 16.85% from 2025 to 2035.
By 2035, the 'Reagents and Consumables' segment is expected to dominate, reaching 350.0 million USD.
Ongoing technological advancements and increasing applications in personalized medicine present significant opportunities, while regulatory hurdles may pose challenges.
Key players in the market include Illumina, BioRad Laboratories, and Thermo Fisher Scientific, among others, contributing to a competitive landscape.
The instruments segment is expected to grow to 250.0 million USD by 2035, indicating substantial growth in demand.
By 2035, the services segment is expected to reach a market value of 305.0 million USD.
Growth is driven by applications in environmental monitoring, clinical diagnostics, and microbiome analysis.
There is a noticeable increase in investment and research initiatives in the US, positioning it as a leading region in this market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Analyst Explore the profile of garvit vyas, one of our esteemed authors at market research future, and access their expert research contributions in the field of market research and industry analysis
Get in Touch
© 2025 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
